Skip to main content

Delayed persistence of elevated monocytic MDSC associates with deleterious outcomes in septic shock: a retrospective cohort study

To the editor,

Recent observations indicate that some septic patients, after inaugural inflammation, enter a stage of protracted immunosuppression that may take weeks/months to vanish and associate with increased rate of secondary infections and mortality [1]. Delayed elevation of myeloid-derived suppressor cells (MDSC) has recently been hypothesized as a key mechanism sustaining sepsis-induced immunosuppression [2, 3]. These cells constitute a heterogeneous population of immature myeloid cells characterized by their capacity to suppress T cell response [4]. There are 3 major MDSC subsets [5]: granulocytic/neutrophilic MDSC (PMN-MDSC phenotypically and morphologically similar to neutrophils), monocytic MDSC (M-MDSC phenotypically and morphologically similar to monocytes), and early MDSC (eMDSC) which are largely immature and do not express any lineage markers. In humans, M-MDSC are mainly defined as CD14+HLA-DRlow monocytes [5]. In various cancers, these cells revealed as valuable predictive markers of pejorative evolution and as potential targets for innovative therapeutic interventions aimed at abrogating their deleterious immunosuppressive properties. Interestingly, our lab has been focusing for years on the monitoring of the decreased expression of HLA-DR on monocytes (mHLA-DR) in septic shock patients (IMMUNOSEPSIS cohort, #NCT02803346) according to a flow cytometry protocol combining CD14 and HLA-DR detections. Results are expressed as numbers of anti-HLA-DR antibodies bound per monocyte (AB/C) [6]. This parameter has been reported as a reliable predictor of deleterious outcomes after sepsis [1].

According to recommendations for M-MDSC characterization, we developed an automated standardized reanalysis protocol (Altrabio algorithm, to investigate our results under a “MDSC” angle (Fig. 1a). The objective was to assess whether, as in cancer, %M-MDSC may provide relevant clinical information. This percentage was recalculated in 301 patients with septic shock (similar to the recent Sepsis-3 criteria). These patients were enrolled from March 2014 to July 2018 and sampled at days 1–2 and/or days 3–4 and days 6–8 (if still present in ICU) after syndrome onset. Mortality, assessed at day 28, was 34%. Fifty patients (15%) developed ICU-acquired infection (HAI). At days 3–4, these patients presented with usual features of sepsis-induced immunosuppression, i.e., very low mHLA-DR (AB/C), 5150 [3115–8250], and severe lymphopenia: CD4 lymphocyte/μL, 362 [245–591].

Fig. 1

Increased %M-MDSC in septic shock patients. a Representative gating strategy used to identify M-MDSC in whole blood from one healthy donor (control) and one patient (septic shock). M-MDSC (%) is the proportion of low HLA-DR monocytes among total CD14+ monocytes. b M-MDSC in patients during the first week after septic shock onset (days 1–2, n = 259; days 3–4, n = 260; and days 6–8, n = 168). Patients’ main characteristics were as follows (% or median ± IQR): 67% male; age, 71 [63–79]; SAPS II at inclusion, 60 [49–73]; SOFA at D1, 9 [7–12]; Charlson, 2 [1–4]; and serum lactate at inclusion (mmol/L), 2.7 [1.8–4.4]. Main diagnosis categories were medical (49%)/surgical (51%), types of infection acquisition were community (55%)/nosocomial (45%), and the most frequent sites of infection were abdominal and pulmonary. Missing values corresponded to patients who died or left ICU before days 6–8 and to missing samples during the weekends for which staining was not possible since lab was not operating 24/7. Seventeen healthy donors served as controls (9 women and 8 men, median age was 49, range 28–62). Comparisons (each time point vs controls) based on Mann-Whitney U test (**p < 0.01)

We observed a marked elevation of M-MDSC in patients in comparison with healthy controls (n = 18, all values < 2%, Fig. 1b). Not surprisingly, there was a strong negative correlation between mHLA-DR and %M-MDSC. Regarding M-MDSC association with deleterious outcomes (i.e., 28-day mortality or HAI), we did not find any difference at the first time points. However, at days 6–8, patients who were going to die or to get infected presented with significantly higher M-MDSC values (Fig. 2a, b). These associations remained significant in multivariate analyses including usual potential confounders (age, gender, SAPS II, SOFA, comorbidities, mechanical ventilation). Calculated odds ratios were 4.4 (p = 0.001) and 2.4 (p = 0.013) for mortality and nosocomial infection occurrence, respectively. Accordingly, Kaplan-Meier representations clearly illustrate the pejorative evolution of patients with the highest M-MDSC values (Fig. 2a, b).

Fig. 2

%M-MDSC at days 6–8 associated with clinical outcomes. a %M-MDSC among total monocyte population at days 6–8 after septic shock according to survival status at day 28: survivors (n = 123) and non-survivors (n = 45). Left, comparison between groups: Mann-Whitney (**p < 0.01). Right, Kaplan-Meier survival curves, patients were stratified in 2 groups based on median %M-MDSC value at days 6–8, difference between curves based on log-rank test. b %M-MDSC among total monocyte population at days 6–8 after septic shock according to the occurrence of health care-associated infections (HAI): patients developing HAI (n = 39) or not (n = 129). Left, comparison between groups: Mann-Whitney (**p < 0.01). Right, cumulative incidence curves for HAI stratified based on median %M-MDSC value at days 6–8, difference between curves based on log-rank test

Due to its retrospective nature, the current report presents with limitations. Indeed, while our findings strongly suggest that CD14+HLA-DRlow cells are M-MDSC, definitive proof of their M-MDSC phenotype is presently lacking (i.e., CD15 staining and functional testing). Awaiting confirmation, they may be called “M-MDSC-like cells.”

Overall, the present results provide robust complementary information to that recently published by Hollen and colleagues [3]. Indeed, we observed that the persistence of increased M-MDSC after 1 week was significantly associated with worsening.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.



Human leukocyte antigen—DR isotype


Myeloid-derived suppressor cells


Antibodies bound per monocyte


Intensive care unit


  1. 1.

    Venet F, Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat Rev Nephrol. 2018;14(2):121–37.

    CAS  Article  Google Scholar 

  2. 2.

    Schrijver IT, Theroude C, Roger T. Myeloid-derived suppressor cells in sepsis. Front Immunol. 2019;10:327.

    CAS  Article  Google Scholar 

  3. 3.

    Hollen MK, Stortz JA, Darden D, Dirain ML, Nacionales DC, Hawkins RB, Cox MC, Lopez MC, Rincon JC, Ungaro R, et al. Myeloid-derived suppressor cell function and epigenetic expression evolves over time after surgical sepsis. Crit Care. 2019;23(1):355.

    Article  Google Scholar 

  4. 4.

    Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108–19.

    CAS  Article  Google Scholar 

  5. 5.

    Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.

    CAS  Article  Google Scholar 

  6. 6.

    Venet F, Lepape A, Monneret G. Clinical review: flow cytometry perspectives in the ICU - from diagnosis of infection to monitoring of injury-induced immune dysfunctions. Crit Care. 2012;15(5):231.

    Article  Google Scholar 

Download references


Not applicable.


This work was supported by Université Lyon 1 and Hospices Civils de Lyon.

Author information




LW, MG, FV, and GM designed and performed the experiments. LW performed the statistical analyses. TR and CM included patients. All authors discussed the data, drafted or revised critically the manuscript for important intellectual content, and approved the final manuscript.

Corresponding author

Correspondence to Guillaume Monneret.

Ethics declarations

Ethics approval and consent to participate

This project was approved by our Institutional Review Board for ethics (“Comité de Protection des Personnes Sud-Est II”, number 11236).This study is registered at the French Ministry of Research and Teaching (#DC-2008-509), at the Commission Nationale de l’Informatique et des Libertés, and on (NCT02803346). Oral information and non-opposition to inclusion in the study were mandatory and recorded in patients’ clinical files. Peripheral blood from healthy volunteers was provided by the “Etablissement Français du Sang” from Lyon. According to EFS standardized procedures for blood donation and to provisions of the articles R.1243–49 and following ones of the French public health code, a written non-opposition to the use of donated blood for research purposes was obtained from HV. The blood donors’ personal data were anonymized before transfer to our research laboratory.

Consent for publication

Not applicable.

Competing interests

The authors declare they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Waeckel, L., Venet, F., Gossez, M. et al. Delayed persistence of elevated monocytic MDSC associates with deleterious outcomes in septic shock: a retrospective cohort study. Crit Care 24, 132 (2020).

Download citation


  • MDSC
  • Sepsis
  • HLA-DR
  • Monocyte
  • Flow cytometry